What is the treatment for a cholinergic crisis due to Ingrezza (valbenazine)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: December 18, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Cholinergic Crisis Due to Ingrezza: Critical Clarification

Ingrezza (valbenazine) does not cause cholinergic crisis—it is a vesicular monoamine transporter 2 (VMAT2) inhibitor used to treat tardive dyskinesia and does not have anticholinesterase activity. 1 This question appears to be based on a fundamental misunderstanding of the drug's mechanism of action.

Understanding the Confusion

  • Ingrezza's mechanism: Valbenazine reversibly inhibits VMAT2, reducing dopamine release at synapses, which helps control involuntary movements in tardive dyskinesia 1
  • Cholinergic crisis causes: True cholinergic crisis results from excessive acetylcholine accumulation due to anticholinesterase agents (organophosphates, nerve agents, or pharmaceutical cholinesterase inhibitors like distigmine or pyridostigmine) 2, 3, 4
  • No mechanistic overlap: Ingrezza does not inhibit cholinesterase and therefore cannot cause acetylcholine accumulation or cholinergic crisis 1

If True Cholinergic Crisis Is Present

If a patient on Ingrezza develops symptoms concerning for cholinergic crisis, consider alternative causes:

Actual Cholinergic Crisis Treatment Algorithm

First-line intervention:

  • Atropine 2-4 mg IV initially for adults, repeated at 5-10 minute intervals until secretions are controlled and muscarinic symptoms resolve 3
  • Pediatric dosing: 0.02-0.05 mg/kg IV, with maximum single dose of 2-3 mg, repeated as needed 3, 5
  • Cumulative doses may reach 10-20 mg in first 2-3 hours or up to 50 mg in 24 hours before full muscarinic antagonism appears 2, 3

Second-line intervention:

  • Pralidoxime (2-PAM) 1000-2000 mg IV over 15-30 minutes for adults to reactivate cholinesterase at nicotinic receptors and reverse muscle paralysis 3
  • Pediatric dosing: 20-50 mg/kg IV 3
  • Must be given early before "aging" of the enzyme-inhibitor bond makes reactivation impossible 2

Seizure control:

  • Benzodiazepines (diazepam 0.2 mg/kg or midazolam 0.05-0.1 mg/kg IV) for anxiety, agitation, or seizures 2, 3

Supportive care:

  • Secure airway and provide mechanical ventilation if respiratory muscle paralysis present 3, 4
  • Frequent airway suctioning for excessive secretions 3
  • Avoid succinylcholine as it may cause prolonged paralysis 3
  • Cardiovascular support with fluids and vasopressors for hypotension 3
  • Continuous cardiac monitoring for bradycardia and arrhythmias 3

Common Pitfalls

  • Underdosing atropine: Severe cholinergic crisis requires much larger atropine doses than standard cardiac dosing—do not hesitate to give repeated doses until secretions dry 2, 3
  • Delayed pralidoxime: Oximes must be given promptly before enzyme aging occurs (within minutes to hours depending on the agent) 2
  • Misdiagnosis: In elderly patients, cholinergic crisis is often misdiagnosed as aspiration pneumonia, delaying appropriate treatment 6

Conclusion on Ingrezza

Ingrezza cannot cause cholinergic crisis. If cholinergic symptoms develop in a patient taking Ingrezza, investigate other exposures to anticholinesterase agents (medications like distigmine for neurogenic bladder, organophosphate pesticides, or other environmental exposures) 4, 6. The treatment algorithm above applies only to true cholinergic crisis from anticholinesterase poisoning, not to any adverse effects of valbenazine.

References

Research

Valbenazine (Ingrezza): The First FDA-Approved Treatment for Tardive Dyskinesia.

P & T : a peer-reviewed journal for formulary management, 2018

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Treatment of Cholinergic Crisis

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Cholinergic Crisis Caused by Cholinesterase Inhibitors: a Retrospective Nationwide Database Study.

Journal of medical toxicology : official journal of the American College of Medical Toxicology, 2018

Guideline

Atropine Dosing in Pediatric Patients

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

[Acute respiratory failure associated with cholinergic crisis: report of five cases and review of the literature].

Nihon Kokyuki Gakkai zasshi = the journal of the Japanese Respiratory Society, 2011

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.